If non‑invasive prenatal testing (NIPT) is negative for all aneuploidies and a 13‑week gestation shows a hypoplastic nasal bone, what is the next step in management?

Management of Hypoplastic Nasal Bone at 13 Weeks with Negative NIPT

When NIPT is negative for all aneuploidies but a hypoplastic nasal bone is identified at 13 weeks, proceed with a comprehensive second-trimester anatomic survey at 18–22 weeks rather than immediately recommending invasive diagnostic testing. 1, 2, 3

Understanding the Clinical Context

Risk Stratification with Negative NIPT

• A negative NIPT result substantially reduces the baseline risk for trisomy 21, as cell-free DNA screening has high sensitivity (>99%) and specificity (>99%) for common aneuploidies. 1
• However, NIPT is a screening test, not a diagnostic test, and can miss subchromosomal aberrations (<20 megabases), monogenic disorders, and has technical limitations including false negatives in 0.1–0.5% of cases. 4, 5

Significance of Hypoplastic Nasal Bone

• An absent or hypoplastic nasal bone occurs in 58–64% of trisomy 21 fetuses but in <1% of chromosomally normal fetuses, making it a strong marker when present. 1
• The presence of a well-formed nasal bone is highly reassuring; conversely, its absence or hypoplasia increases concern—but this must be interpreted in the context of other findings. 1
• In one recent study, the prevalence of Down syndrome in fetuses with absent/hypoplastic nasal bone was 8.5% overall, but this included cases without prior NIPT screening. 3

Recommended Management Algorithm

Step 1: Verify Measurement Quality

• Ensure the nasal bone assessment was performed by a qualified sonographer using standardized technique, as significant inter- and intra-observer variability exists in first-trimester measurements. 2
• Consider repeat ultrasound by a maternal-fetal medicine specialist if initial measurement quality is uncertain. 2

Step 2: Assess for Additional Markers

• If the hypoplastic nasal bone is truly isolated (normal nuchal translucency <3.0 mm, no other structural anomalies or soft markers), the risk remains substantially lower than if multiple markers are present. 1, 3
• Document the nuchal translucency measurement; NT <3.0 mm is reassuring and requires only routine follow-up, whereas NT ≥3.0 mm mandates immediate further evaluation. 2

Step 3: Comprehensive Second-Trimester Anatomic Survey

• A detailed anatomic scan at 18–22 weeks is mandatory regardless of NIPT results, as 50–75% of trisomy 21 fetuses exhibit detectable structural anomalies by mid-trimester. 1, 2
• This survey should specifically evaluate for soft markers including echogenic intracardiac focus, shortened long bones, echogenic bowel, thickened nuchal fold, and major structural anomalies. 1
• A normal detailed anatomy scan reduces the probability of trisomy 21 by approximately 90–95% when combined with negative NIPT and normal NT. 1

Step 4: Genetic Counseling and Shared Decision-Making

• Offer genetic counseling to discuss the residual risk and the option of diagnostic testing versus continued surveillance. 1, 3
• Emphasize that while negative NIPT is highly reassuring, it does not eliminate all genetic risk, particularly for subchromosomal abnormalities and monogenic conditions. 4, 5

When to Offer Invasive Diagnostic Testing

Indications for Amniocentesis

• Invasive testing should be offered (not mandated) when:
  • Hypoplastic nasal bone is associated with other structural anomalies or multiple soft markers. 3
  • The patient desires definitive chromosomal diagnosis despite reassuring NIPT. 1
  • Additional concerning findings emerge on the second-trimester anatomy scan. 1, 3

Testing Modality

• Chromosomal microarray is preferred over standard karyotype when invasive testing is performed, as it detects clinically significant copy-number variants that NIPT may miss and has higher sensitivity for chromosomal aberrations. 1, 3
• The procedure-related pregnancy loss risk from amniocentesis is approximately 1 in 300–500. 1

Alternative Strategies if Invasive Testing Declined

Non-Invasive Options

• Repeat cell-free DNA screening can be considered for additional risk stratification, though this is not standard practice for isolated soft markers with negative initial NIPT. 1
• Second-trimester quad screen detects approximately 80–85% of trisomy 21 cases but provides less reassurance than repeat NIPT. 1

Ongoing Surveillance

• Standard third-trimester growth monitoring and routine prenatal care are sufficient when NIPT is negative and anatomy scan is normal. 1
• No specialized surveillance beyond routine care is indicated based solely on isolated hypoplastic nasal bone with negative NIPT. 1

Critical Pitfalls to Avoid

• Do not dismiss the hypoplastic nasal bone finding entirely simply because NIPT is negative; it warrants documentation and appropriate follow-up imaging. 1, 3
• Do not immediately recommend invasive testing for isolated hypoplastic nasal bone when NIPT is negative and NT is normal, as this increases procedure-related risks without proportionate benefit. 3
• Do not assume normal ultrasound eliminates all genetic risk, as both NIPT and imaging can miss certain chromosomal abnormalities, microdeletions, and structural variants. 1, 4
• Do not equate a soft marker with a definitive diagnosis; the combination of negative NIPT and isolated hypoplastic nasal bone yields a residual risk substantially lower than the procedure-related loss risk from amniocentesis. 1, 3
• Do not withhold the option of diagnostic testing from patients who desire absolute certainty, as this respects patient autonomy. 1